Skip to main content
MedVellum
MCQsExamsAtlas
DashboardPricing
MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳

MedVellum.

The folio

Exam-exhaustive medical education across every specialty — evidence-graded topics, engraved plates, and practice in every written and oral format. Educational content only — not medical advice.

llms.txt · psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship
  • Paediatrics Fellowship
  • Physician Medicine

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Folio edition · Set in Instrument Serif & Archivo

Paeds Vivasfetal-neonatal-and-perinatal

Paeds Vivas · fetal-neonatal-and-perinatal

Respiratory distress syndrome of prematurity — branching viva

Viva on the surfactant-deficiency mechanism, the management ladder, oxygen targeting, surfactant dosing and the prevention of bronchopulmonary dysplasia.

branching clinical structured oral
On this page & tools

Target exams

RACP DCEMRCPCH ClinicalRCPSC Pediatrics

Target exams

RACP DCEMRCPCH ClinicalRCPSC Pediatrics
Prompt
A 27-week gestation preterm infant is on nasal CPAP in the first two hours of life with grunting, retractions and a rising inspired oxygen; the candidate must explain the mechanism, justify the surfactant decision, set the oxygen target and plan the prevention of bronchopulmonary dysplasia.

Branch 1 — Mechanism and recognition

The examiner opens: "Explain why this infant is in distress." A strong candidate traces surfactant deficiency through raised surface tension, alveolar collapse at end-expiration, low functional residual capacity and compliance, ventilation-perfusion mismatch with hypoxaemia and hypercapnia, and acidosis that further inhibits surfactant and constricts the pulmonary vasculature. The candidate then names expiratory grunting as auto-positive end-expiratory pressure and explains the chest radiograph triad of low volumes, granular opacities and air bronchograms. [1]

Branch 2 — Surfactant and the support ladder

The examiner pivots: "The FiO2 is now 0.35. What now?" The candidate states that the 2022 European guideline threshold of FiO2 over 0.30 on CPAP has been met, continues CPAP at 5 to 7 cm of water, and gives surfactant — poractant alfa 200 mg per kilogram — preferring the LISA or MIST technique to avoid intubation, with intubation reserved for failure of CPAP. The candidate explains that after surfactant the ventilator must be weaned promptly as compliance rises, to avoid volutrauma and air leak. [1] [2] [7]

Branch 3 — Oxygen targeting and caffeine

The examiner presses on targets: "What saturation do you aim for and why?" The candidate targets 91 to 95 percent beyond the first minutes, citing the NeOProM meta-analysis showing that the higher target reduced mortality while the lower target reduced retinopathy but increased death. The candidate adds caffeine citrate — 20 mg per kilogram loading then 5 to 10 mg per kilogram daily — citing the CAP trial for reduced apnoea and improved survival without disability. [5] [8]

Branch 4 — Complications and prevention of BPD

The examiner closes on the long view: "What are you trying to prevent?" The candidate names bronchopulmonary dysplasia, defined by oxygen or support at 36 weeks' postmenstrual age, and the acute complications of pneumothorax, pulmonary haemorrhage and intraventricular haemorrhage. The prevention bundle is antenatal corticosteroids, gentle ventilation, early surfactant, caffeine, and avoiding hyperoxia and volutrauma, with long-term follow-up for growth, neurodevelopment, audiology and retinopathy. [1]

References

  1. [1]Sweet DG European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update. Neonatology, 2023.PMID 36863329
  2. [2]Polin RA Surfactant replacement therapy for preterm and term neonates with respiratory distress. Pediatrics, 2014.PMID 24379227
  3. [5]Askie LM Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA, 2018.PMID 29872859
  4. [7]Morley CJ Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med, 2008.PMID 18272893
  5. [8]Schmidt B Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med, 2007.PMID 17989382